

## Topical Collection

# The Safety and Immunogenicity of the Bivalent Omicron-Containing mRNA-1273.214 Booster Vaccine

### Message from the Collection Editors

A bivalent vaccine from Moderna based on omicron BA.1 was approved for use as a booster dose by the Medicines and Healthcare Products Regulatory Agency. Preliminary data indicated that the vaccine generates a strong immune response against the BA.4 and BA.5 subvariants, which are now dominant worldwide. This new proposal behaves in the same manner as a flu-like situation, where everyone must take their flu vaccine at the start of winter each year and the composition of the vaccine is regularly modified in accordance with circulating strains. The new vaccines are highly effective in preventing disease severity but not transmission. We are pleased to invite you to submit to this Topical Collection for all kinds of manuscripts, such as research articles, brief reports, and communications to promote the knowledge and discussion about COVID-19 vaccines, especially bivalent vaccines. The invited papers broadly cover the safety and immunogenicity of COVID-19 vaccines in normal healthy persons, persons with moderate immunocompromised status and persons with severe immunocompromised status.

### Collection Editors

Dr. Lalit Batra

Regional Biocontainment Laboratory (RBL), Center for Predictive Medicine, University of Louisville, Louisville, KY 40292, USA

Dr. Shailendra Kumar Verma

Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/146282](https://mdpi.com/si/146282)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).